Intech Investment Management LLC Buys Shares of 4,844 GeneDx Holdings Corp. (NASDAQ:WGS)

Intech Investment Management LLC acquired a new position in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 4,844 shares of the company's stock, valued at approximately $372,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. MCF Advisors LLC raised its holdings in shares of GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after buying an additional 182 shares during the last quarter. Global Retirement Partners LLC acquired a new stake in GeneDx in the 4th quarter valued at approximately $28,000. Evolution Wealth Advisors LLC bought a new stake in GeneDx during the 4th quarter valued at $202,000. Victory Capital Management Inc. acquired a new position in GeneDx during the 4th quarter worth $209,000. Finally, Ieq Capital LLC bought a new position in shares of GeneDx in the fourth quarter worth $220,000. 61.72% of the stock is currently owned by institutional investors.

GeneDx Price Performance

NASDAQ:WGS traded down $2.14 during mid-day trading on Friday, reaching $92.20. 515,443 shares of the stock were exchanged, compared to its average volume of 642,815. GeneDx Holdings Corp. has a 1-year low of $8.53 and a 1-year high of $115.60. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $2.59 billion, a PE ratio of -47.04 and a beta of 1.91. The business has a fifty day moving average price of $87.28 and a 200 day moving average price of $74.20.

Remove Ads

GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The company had revenue of $95.64 million for the quarter, compared to analysts' expectations of $82.24 million. Research analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Kevin Feeley sold 1,430 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $76.04, for a total value of $108,737.20. Following the completion of the sale, the chief financial officer now directly owns 26,770 shares of the company's stock, valued at $2,035,590.80. This represents a 5.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Katherine Stueland sold 18,006 shares of the business's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $78.18, for a total transaction of $1,407,709.08. Following the transaction, the chief executive officer now directly owns 53,140 shares in the company, valued at $4,154,485.20. The trade was a 25.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 183,032 shares of company stock valued at $17,007,198 over the last three months. Insiders own 27.30% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. The Goldman Sachs Group lifted their price objective on shares of GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research note on Wednesday, February 19th. TD Cowen boosted their price target on shares of GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a research report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $72.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.